Literature DB >> 15133080

Intron-containing beta-tubulin transcripts in Cryptosporidium parvum cultured in vitro.

Xiaomin Cai1, Cheryl A Lancto2, Mitchell S Abrahamsen2, Guan Zhu3,1.   

Abstract

The genome of Cryptosporidium parvum contains a relatively small number of introns, which includes the beta-tubulin gene with only a single intron. Recently, it was observed that the intron was not removed from some of the beta-tubulin transcripts in the late life cycle stages cultured in vitro. Although normally spliced beta-tubulin mRNA was detected in all parasite intracellular stages by RT-PCR (e.g. HCT-8 or Caco-2 cells infected with C. parvum for 12-72 h), at 48-72 h post-infection unprocessed beta-tubulin transcripts containing intact introns started to appear in parasite mRNA within infected host cells. The intron-containing transcripts could be detected by fluorescence in situ hybridization (FISH) using an intron-specific probe. The intron-containing beta-tubulin transcripts appeared unique to the in vitro-cultured C. parvum, since they were not detected in parasite-infected calves at 72 h. As yet, it is unclear whether the late life cycle stages of C. parvum are partially deficient in intron-splicing or the intron-splicing processes have merely slowed, both of which would allow the detection of intron-containing transcripts. Another possible explanation is that the decay in transcript processing might simply be due to the onset of parasite death. Nonetheless, the appearance of intron-containing transcripts coincides with the arrest of C. parvum development in vitro. This unusual observation prompts speculation that the abnormal intron-splicing of beta-tubulin transcripts may be one of the factors preventing complete development of this parasite in vitro. Furthermore, the presence of both processed and unprocessed introns in beta-tubulin transcripts in vitro may provide a venue for studying overall mechanisms for intron-splicing in this parasite.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133080     DOI: 10.1099/mic.0.26897-0

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  7 in total

1.  Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).

Authors:  Jason M Fritzler; Guan Zhu
Journal:  J Antimicrob Chemother       Date:  2011-12-13       Impact factor: 5.790

2.  Functional characterization of an evolutionarily distinct phosphopantetheinyl transferase in the apicomplexan Cryptosporidium parvum.

Authors:  Xiaomin Cai; Dustin Herschap; Guan Zhu
Journal:  Eukaryot Cell       Date:  2005-07

3.  Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro.

Authors:  Xiaomin Cai; Keith M Woods; Steve J Upton; Guan Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Enrichment of Cryptosporidium parvum from in vitro culture as measured by total RNA and subsequent sequence analysis.

Authors:  Jessica C Kissinger; Karen E Hermetz; Keith M Woods; Steve J Upton
Journal:  Mol Biochem Parasitol       Date:  2017-12-29       Impact factor: 1.759

5.  The apicomplexan Cryptosporidium parvum possesses a single mitochondrial-type ferredoxin and ferredoxin:NADP+ reductase system.

Authors:  Cheng Lei; S Dean Rider; Cai Wang; Haili Zhang; Xiangshi Tan; Guan Zhu
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

6.  Expression of an intron-containing beta-tubulin mRNA in catfish olfactory epithelium.

Authors:  Ezio Bettini; Frank L Margolis
Journal:  J Mol Histol       Date:  2007-09-12       Impact factor: 2.611

7.  m6A mRNA Methylation Regulates Epithelial Innate Antimicrobial Defense Against Cryptosporidial Infection.

Authors:  Zijie Xia; Jihao Xu; Eugene Lu; Wei He; Silu Deng; Ai-Yu Gong; Juliane Strass-Soukup; Gislaine A Martins; Guoqing Lu; Xian-Ming Chen
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.